Vanda Pharmaceuticals

FDA approves Hetlioz for sleep-wake disorder in blind individuals

Monday, February 3, 2014 10:38 AM

The FDA approved Hetlioz (tasimelteon), a melatonin receptor agonist, to treat non-24- hour sleep-wake disorder (non-24) in totally blind individuals. Non-24 is a chronic circadian rhythm (body clock) disorder in the blind that causes problems with the timing of sleep. This is the first FDA approval of a treatment for the disorder.

More... »

WIRB Copernicus Group

Vanda lands exclusive world-wide license for VLY-686 from Lilly

Monday, April 16, 2012 11:40 AM

Vanda Pharmaceuticals, a biopharmaceutical company focused on central nervous system disorders, has acquired an exclusive world-wide license from Eli Lilly to develop and commercialize a small molecule neurokinin 1 receptor (NK-1R) antagonist for all human indications.

More... »

CRF Health eCOA webinar series

Tasimelteon could reset body’s clock in sleep-wake disorder

Friday, January 27, 2012 02:17 PM

Vanda Pharmaceuticals’ compound tasimelteon has shown for the first time to reset the body clock and to align it to a constant 24-hour day in patients suffering from Non-24-Hour Sleep-Wake Disorder. Tasimelteon is a circadian regulator in development for the treatment of the sleep-wake disorder in completely blind individuals with no light perception.

More... »

Vanda, Biotoscana enter exclusive license agreement

Monday, August 1, 2011 01:17 PM

Vanda Pharmaceuticals, a biopharmaceutical company, has entered into an exclusive license agreement with Argentina-based Biotoscana Farma, a wholly owned affiliate of Biotoscana International, based in Bogota, Colombia, for the commercialization of Fanapt in Argentina.

More... »

Vanda begins trial for long-acting injectable to treat schizophrenia

Monday, April 11, 2011 12:52 PM

Vanda Pharmaceuticals and Novartis Pharmaceuticals, an affiliate of Vanda's sublicensor Novartis Pharma AG, has initiated a clinical study to evaluate the long-acting injectable (or depot) formulation of Fanapt (iloperidone).  This is a phase I study that will evaluate the safety and pharmacokinetic profiles of two different long-acting formulations of Fanapt in patients with schizophrenia.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs